Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-07), Zhejiang Nhu Co's Beta is 0.6114.
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Zhejiang Nhu Co Beta Related Terms
Zhejiang Nhu Co Beta Historical Data
* Premium members only.
The historical data trend for Zhejiang Nhu Co's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Nhu Co Beta vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's Beta distribution charts can be found below:
* The bar in red indicates where Zhejiang Nhu Co's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Zhejiang Nhu Co (SZSE:002001) has a Beta of 0.6114 as of Sep. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zhejiang Nhu Co and its competitors.
Is Zhejiang Nhu Co's Beta too high?
Zhejiang Nhu Co's current Beta is 0.6114. Overall, Zhejiang Nhu Co has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Nhu Co's Beta compare to ZTS?
Zhejiang Nhu Co's Beta of 0.6114 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Zhejiang Nhu Co and its competitors. Zhejiang Nhu Co's current Beta is 0.6114. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Nhu Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Nhu Co (SZSE:002001) is currently considered Fairly Valued. The stock's GF Value™ is ¥28.59, compared to a current price of ¥26.55 — trading 7.1% below its estimated fair value. The current Beta is 0.6114. Zhejiang Nhu Co's overall GF Score™ is 98/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Zhejiang Nhu Co (SZSE:002001), the current Beta is 0.6114 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Nhu Co (SZSE:002001) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Nhu Co stock appears to be undervalued.
The current stock price of ¥26.55 is trading 7.1% below its estimated GF Value™ of ¥28.59.
GuruFocus considers Zhejiang Nhu Co to be Fairly Valued.
Key valuation signals for SZSE:002001:
Beta: 0.6114
GF Value™: ¥28.59 vs. price of ¥26.55 (7.1% below fair value)
No single metric tells the full story. See the SZSE:002001 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives, and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer, and Anti-bacterial, with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3, and coenzyme Q10, and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.
98GF Score
Get the complete analysis for SZSE:002001
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:002001 has been successfully added to your 
